The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Identification of a Plasma Proteomic Signature for Lung Cancer
Official Title: Identification of a Plasma Proteomic Signature for Lung Cancer
Study ID: NCT01752101
Brief Summary: The primary objective is to identify a panel of plasma and/or serum proteins that differentiates the absence or presence of lung malignancy in samples obtained from subjects enrolled in this IRB/EC approved study with pulmonary nodules.
Detailed Description: Blood samples are obtained from those patients undergoing procedures to determine if a lung nodule is benign or cancerous. The data from the study will not be used to guide or influence the treatment of the patients enrolled in this study. There is no change from the normal standard of care that patients receive.
Minimum Age: 40 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Kaiser Permanente Northern California, San Francisco, California, United States
University of Miami - Sylvester Comprehensive Cancer Center, Miami, Florida, United States
North East Alabama Regional Medical Center, Anniston, Georgia, United States
Greater Baltimore Medical Center, Baltimore, Maryland, United States
Lahey Hospital & Medical Center, Burlington, Massachusetts, United States
Henry Ford Hospital, Detroit, Michigan, United States
Mayo Clinic, Rochester, Minnesota, United States
University of Cincinnati, Cincinnati, Ohio, United States
Geisinger Medical Center, Danville, Pennsylvania, United States
Cardiopulmonary Research Science and Technology Institute, Dallas, Texas, United States
Intermountain Healthcare, Murray, Utah, United States
Group Health Research Institute, Seattle, Washington, United States
Name: Russell F. Hudnall
Affiliation: Integrated Diagnostics, Inc.
Role: STUDY_DIRECTOR